

## Clinical Policy: Zilucoplan (Zilbrysq)

Reference Number: PA.CP.PHAR.616

Effective Date: 02/2024

Last Review Date: 04/2026

### Description

Zilucoplan (Zilbrysq<sup>®</sup>) is a complement inhibitor.

### FDA Approved Indication(s)

Zilbrysq is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of PA Health & Wellness<sup>®</sup> that Zilbrysq is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Generalized Myasthenia Gravis (must meet all):

1. Diagnosis of gMG;
2. Prescribed by or in consultation with a neurologist;
3. Age  $\geq$  18 years;
4. Myasthenia Gravis-Activities of Daily Living (MG-ADL) score  $\geq$  6 at baseline;
5. Myasthenia Gravis Foundation of America (MGFA) clinical classification of Class II to IV;
6. Member has positive serologic test for anti-AChR antibodies;
7. Failure of a corticosteroid (*see Appendix B*), unless contraindicated or clinically significant adverse effects are experienced;
8. Failure of a cholinesterase inhibitor (*see Appendix B*), unless contraindicated or clinically significant adverse effects are experienced;
9. Failure of at least one non-steroidal immunosuppressive therapy (*see Appendix B*), unless clinically significant adverse effects are experienced or all are contraindicated;
10. Failure of Ultomiris<sup>®</sup> at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
11. Zilbrysq is not prescribed concurrently with Imaavy<sup>™</sup>, Soliris<sup>®</sup>/Bkembv<sup>™</sup>/Epysqli<sup>®</sup>, Ultomiris<sup>®</sup>, Rystiggo<sup>®</sup>, Vyvgart<sup>®</sup> or Vyvgart<sup>®</sup> Hytrulo;
12. Documentation of member's current weight in kg;
13. Dose does not exceed the following (a and b):
  - a. One of the following (i, ii, or iii):
    - i. Weight < 56 kg: 16.6 mg per day;
    - ii. Weight 56 kg to < 77 kg: 23 mg per day;
    - iii. Weight  $\geq$  77 kg: 32.4 mg per day;
  - b. 1 prefilled syringe per day.

**Approval duration: 12 months**

**B. Other diagnoses/indications**

1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

**II. Continued Therapy**

**A. Generalized Myasthenia Gravis (must meet all):**

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies;
2. Member is responding positively to therapy as evidenced by a  $\geq 2$ -point reduction from baseline in the MG-ADL total score;
3. Zilbrysq is not prescribed concurrently with Imaavy, Soliris/Bkemv/Epysqli, Ultomiris, Rystiggo, Vyvgart or Vyvgart Hytrulo;
4. Documentation of member's current weight in kg;
5. If request is for a dose increase, new dose does not exceed the following (a and b):
  - a. One of the following (i, ii, or iii):
    - i. Weight  $< 56$  kg: 16.6 mg per day;
    - ii. Weight 56 kg to  $< 77$  kg: 23 mg per day;
    - iii. Weight  $\geq 77$  kg: 32.4 mg per day;
  - b. 1 prefilled syringe per day.

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies.

**Approval duration: Duration of request or 12 months (whichever is less); or**

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – PA.CP.PMN.53

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

AChR: acetylcholine receptor

FDA: Food and Drug Administration

gMG: generalized myasthenia gravis

MG-ADL: Myasthenia Gravis-Activities of Daily Living

MGFA: Myasthenia Gravis Foundation of America

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
<b>Corticosteroids</b>		
betamethasone	Oral: 0.6 to 7.2 mg PO per day	7.2 mg/day
dexamethasone	Oral: 0.75 to 9 mg/day PO	9 mg/day
methylprednisolone	Oral: 12 to 20 mg PO per day; increase as needed by 4 mg every 2-3 days until there is marked clinical improvement	40 mg/day
prednisone	Oral: 15 mg/day to 20 mg/day; increase by 5 mg every 2-3 days as needed	60 mg/day
<b>Cholinesterase Inhibitors</b>		
pyridostigmine (Mestinon <sup>®</sup> )	Oral immediate-release: 600 mg daily in divided doses (range, 60-1,500 mg daily in divided doses) Oral sustained release: 180-540 mg QD or BID	Immediate-release: 1,500 mg/day Sustained-release: 1,080 mg/day
neostigmine (Bloxivert <sup>®</sup> )	Oral: 15 mg TID. The daily dosage should be gradually increased at intervals of 1 or more days. The usual maintenance dosage is 15-375 mg/day (average 150 mg) IM or SC: 0.5 mg based on response to therapy	Oral: 375 mg/day
<b>Non-Steroidal Immunosuppressants</b>		
azathioprine (Imuran <sup>®</sup> )	Oral: 50 mg QD for 1 week, then increase gradually to 2 to 3 mg/kg/day	3 mg/kg/day
mycophenolate mofetil (Cellcept <sup>®</sup> )*	Oral: Dosage not established. 1 gram BID has been used with adjunctive corticosteroids or other non-steroidal immunosuppressive medications	2 g/day
cyclosporine (Sandimmune <sup>®</sup> )*	Oral: initial dose of cyclosporine (non-modified), 5 mg/kg/day in 2 divided doses	5 mg/kg/day
Rituxan <sup>®</sup> (rituximab), Riabni <sup>™</sup> (rituximab-arrx), Ruxience <sup>™</sup> (rituximab-pvvr), Truxima <sup>®</sup> (rituximab-abbs)*†	IV: 375 mg/m <sup>2</sup> once a week for 4 weeks; an additional 375 mg/m <sup>2</sup> dose may be given every 1 to 3 months afterwards	375 mg/m <sup>2</sup>
<b>Complement Inhibitor</b>		
Ultomiris	<b>gMG</b>	3,600 mg/

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose												
(ravulizumab-cwvz)	<table border="1"> <thead> <tr> <th>Body Weight Range (kg)</th> <th>Loading Dose (mg)</th> <th>Maintenance Dose (mg)</th> </tr> </thead> <tbody> <tr> <td>≥ 40 to &lt; 60</td> <td>2,400</td> <td>3,000 every 8 weeks</td> </tr> <tr> <td>≥ 60 to &lt; 100</td> <td>2,700</td> <td>3,300 every 8 weeks</td> </tr> <tr> <td>≥ 100</td> <td>3,000</td> <td>3,600 every 8 weeks</td> </tr> </tbody> </table> <p>Day 1: Loading dose IV Day 15 and thereafter: Maintenance dose IV</p>	Body Weight Range (kg)	Loading Dose (mg)	Maintenance Dose (mg)	≥ 40 to < 60	2,400	3,000 every 8 weeks	≥ 60 to < 100	2,700	3,300 every 8 weeks	≥ 100	3,000	3,600 every 8 weeks	8 weeks
Body Weight Range (kg)	Loading Dose (mg)	Maintenance Dose (mg)												
≥ 40 to < 60	2,400	3,000 every 8 weeks												
≥ 60 to < 100	2,700	3,300 every 8 weeks												
≥ 100	3,000	3,600 every 8 weeks												

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

\*Off-label

†Prior authorization is required for rituximab products

#### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): unresolved *Neisseria meningitidis* infection
- Boxed warning(s): serious meningococcal infections

#### Appendix D: General Information

- Zilbrysq is only available through a REMS (Risk Evaluation and Mitigation Strategy) program due to the risk of life-threatening and fatal meningococcal infection. Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Zilbrysq and revaccinated according to current medical guidelines for vaccine use. Patients should be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics if necessary.
- The MG-ADL scale is an 8-item patient-reported scale that measures functional status in 8 domains related to MG – talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop. Each domain is given a score of 0-3, with 0 being normal and 3 being most severe impairment. A 2-point decrease in the MG-ADL score is considered a clinically meaningful response.

## V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
gMG	Weight < 56 kg: 16.6 mg SC QD Weight 56 kg to < 77 kg: 23 mg SC QD Weight ≥ 77 kg: 32.4 mg SC QD	See regimen

## VI. Product Availability

Single-dose prefilled syringes: 16.6 mg/0.416 mL, 23 mg/0.574 mL, 32.4 mg/0.81 mL

## VII. References

1. Zilbrysq Prescribing Information. Smyrna, GA: UCB, Inc., February 2025. Available at: <https://www.zilbrysq.com>. Accessed October 23, 2025.

2. UCB. UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis. Published May 10, 2022. Available at: <https://www.ucb.com/stories-media/Press-Releases/article/UCB-presents-efficacy-and-safety-results-for-zilucoplan-and-rozanolixizumab-in-generalized-myasthenia-gravis>. Accessed November 5, 2025.
3. Ra Pharmaceuticals. A phase 3, multicenter, randomized, double blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of zilucoplan in subjects with generalized myasthenia gravis. [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04115293). Available at: <https://clinicaltrials.gov/ct2/show/study/NCT04115293>. Accessed November 5, 2025.
4. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of Myasthenia Gravis. *Neurology*. 2020;96(3):114-122.
5. Treatment strategy. Myasthenia Gravis Foundation of America. Available at: <https://myasthenia.org/Newly-Diagnosed/Treatment-Strategy>. Accessed November 5, 2025.
6. Muppidi S, Silvestri N, Tan R, et al. The evolution of Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale utilization to measure myasthenia gravis symptoms and treatment response (1817). *Neurology*. 2021;96(15 Suppl):1817.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
C9399	Unclassified drugs or biologicals
J3490	Unclassified drugs

Reviews, Revisions, and Approvals	Date
Policy created	01/2024
1Q 2025 annual review: no significant changes; added Bkerv, Epysqli, and Rystiggo to the list of therapies that Zilbrysq should not be prescribed concurrently with; references reviewed and updated.	01/2025
1Q 2026 annual review: clarified that the required immunosuppressive therapy should be non-steroidal; added Imaavy and Vyvgart Hytrulo to the list of therapies that Zilbrysq should not be prescribed concurrently with; extended approval durations from 6 to 12 months as gMG is a chronic condition; references reviewed and updated.	01/2026
Per March SDC, added redirection to Ultomiris.	04/2026